Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

DRUG: Doravirine
DRUG: 2 NRTIs
DRUG: DOR/3TC/TDF

Sponsor

Merck Sharp & Dohme LLC